GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (NAS:SUPN) » Definitions » Degree of Operating Leverage

SUPN (Supernus Pharmaceuticals) Degree of Operating Leverage : -92.35 (As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is Supernus Pharmaceuticals Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Supernus Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -92.35. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Supernus Pharmaceuticals's Degree of Operating Leverage or its related term are showing as below:

SUPN's Degree of Operating Leverage is ranked better than
97.37% of 950 companies
in the Drug Manufacturers industry
Industry Median: 0.64 vs SUPN: -92.35

Supernus Pharmaceuticals Degree of Operating Leverage Historical Data

The historical data trend for Supernus Pharmaceuticals's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Degree of Operating Leverage Chart

Supernus Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.40 -4.36 -1.98 10.32 190.36

Supernus Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.86 -3.13 9.74 190.36 -92.35

Competitive Comparison of Supernus Pharmaceuticals's Degree of Operating Leverage

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals's Degree of Operating Leverage Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Degree of Operating Leverage falls into.


;
;

Supernus Pharmaceuticals Degree of Operating Leverage Calculation

Supernus Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( 95.031 (Mar. 2025) / -9.586 (Mar. 2024) - 1 )/( 667.997 (Mar. 2025) / 597.401 (Mar. 2024) - 1 )
=-10.9135/0.1182
=-92.35***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Supernus Pharmaceuticals  (NAS:SUPN) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Supernus Pharmaceuticals Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Supernus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
Executives
Jonathan Rubin officer: SVP, Chief Medical Officer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Padmanabh P. Bhatt officer: Sr. VP of IP, CSO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Newhall Charles W Iii director 1119 ST PAUL ST, BALTIMORE MD 21202
Frederick M. Hudson director 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Jack A. Khattar director, officer: President, CEO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Georges Gemayel director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Frank Mottola officer: Sr VP, Quality, GMP Oper. & IT 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Tami Tillotson Martin officer: Sr. V.P., Regulatory Affairs C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Bethany Sensenig director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Timothy C Dec officer: Senior Vice-President & CFO C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Schwabe Stefan K.f. officer: Executive Vice President R&D C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Gregory S Patrick officer: VP, Chief Financial Officer C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
James Patrick Kelly officer: Executive Vice-President & CFO C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Carrolee Barlow director C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE MD 20850
Victor Vaughn officer: Sr. VP of Sales C/O SUPERNUS PHARMACEUTICALS, INC., 1550 EAST GUDE DRIVE, ROCKVILLE MD 20850